Skip to content

Author

G. Sirgiovanni

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pembrolizumab plus lenvatinib in first-line metastatic renal cell carcinoma: a single-institution experience and a case of severe treatment-related toxicity with durable tumour control

Background: Pembrolizumab plus lenvatinib is a standard first-line treatment for metastatic renal cell carcinoma (mRCC) based on the phase III CLEAR trial. Real- world data are needed to assess effectiveness and toxicity management in routine practice. We report a retrospective single-institution experience and a case...

A. Malgeri, G. Sirgiovanni, L. Cerbone et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.